Amendments to the Claims

The following listing of claims will replace all prior versions and listing of claims in the

application.

What is claimed is:

1. (Currently amended) A method of identifying a compound capable of modulating the activity

of Cathepsin Z in [[a]] an antigen-presenting dendritic cell, comprising the steps of:

(a) measuring said cell's base level of Cathepsin Z activity in the absence of a

candidate compound;

(b) introducing said candidate compound; and

(c) measuring said cell's level of Cathepsin Z activity in the presence of said

candidate compound.

2. (Original) The method of Claim 1 wherein said cell's level of Cathepsin Z activity is measured

by measuring antigen presentation.

3. (Original) The method of Claim 2, wherein said cell's level of antigen presentation is

measured by measuring autologous T-cell response to tetanus toxin.

4. (Original) The method of Claim 2, wherein said cell's level of antigen presentation is

measured by measuring said cell's capacity to present quenched FITC-ovalbumin.

5 - 8. (Cancelled)

9. (Currently amended) A method for treating an autoimmune disease comprising the step of

administering the a pharmaceutical of Claim-8 comprising the compound capable of

modulating the activity of Cathepsin Z in the antigen-presenting dendritic cell identified

by the method of claim 1.

Docket No.: USAV2003/0020 US PCT

Application No.: 10/596,815

2 of 7

| 10. (Original) The method of Claim 9 wherein said autoimmune disease is selected from the group consisting of rheumatoid arthritis and multiple sclerosis. | |
|--|--|
| | |
| | |
| | |
| | |

Dozket No. USAV2003 6020 US PCT application No.: 10 596/815